Quarterly Updates28 Jul 2025, 03:25 pm
Ajanta Pharma Reports 14% Revenue Growth in Q1 FY 2026
AI Summary
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported an excellent performance for the quarter ended 30 June 2025. The company's revenue from operations stood at Rs. 1,303 crores, marking a 14% growth compared to Q1 FY 2025. EBITDA was up 6% to Rs. 351 crores, and profit after tax (PAT) increased by 4% to Rs. 255 crores. Excluding the impact of mark-to-market forex loss, EBITDA stood at Rs. 376 crores, reflecting a 14% growth, and PAT grew by 12%. Cashflow from operations (CFO) was Rs. 282 crores, and free cashflow (FCF) was Rs. 209 crores. ROCE stood at a healthy level of 33% and RONW at 26%.
Key Highlights
- Revenue from operations up by 14%
- EBITDA up 6% and PAT up 4%
- Excluding forex loss, EBITDA up 14% and PAT up 12%
- Cashflow from operations at Rs. 282 crores
- Free cashflow at Rs. 209 crores